Status:
UNKNOWN
Real World Data Analysis of PARP Inhibitors Use in Patients With Ovarian Cancer
Lead Sponsor:
Hellenic Cooperative Oncology Group
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18-80 years
Brief Summary
Real-world clinical outcomes and toxicity data will be evaluated in patients with advanced high grade ovarian cancer who will receive PARP inhibitors.
Detailed Description
A prospective-retrospective analysis of patients with histologically confirmed high grade ovarian cancer who will receive or received olaparib or niraparib will be conducted at any line of treatment.
Eligibility Criteria
Inclusion
- \- women \>18 years old with advanced high grade ovarian cancer
Exclusion
- \-
Key Trial Info
Start Date :
November 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 30 2023
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT04724031
Start Date
November 1 2019
End Date
September 30 2023
Last Update
March 14 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Adamantia Nikolaidi
Athens, Attica, Greece, 15321